| 1 |
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315 (8): 801-810.
|
| 2 |
Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations[J]. Am J Respir Crit Care Med, 2016, 193 (3): 259-572.
|
| 3 |
Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, et al. The global burden of paediatric and neonatal sepsis: a systematic review[J]. Lancet Respir Med, 2018, 6 (3): 223-230.
|
| 4 |
Phua J, Ngerng W, See K, et al. Characteristics and outcomes of culture-negative versus culture-positive severe sepsis[J]. Crit Care, 2013, 17 (5): R202.
|
| 5 |
Southeast Asia Infectious Disease Clinical Research Network. Causes and outcomes of sepsis in southeast Asia: a multinational multicentre cross-sectional study[J]. Lancet Glob Health, 2017, 5 (2): e157-e167.
|
| 6 |
Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis[J]. Lancet, 2017, 390 (10104): 1770-1780.
|
| 7 |
World Health Organization. Vaccines against influenza WHO position paper-November 2012[J]. Wkly Epidemiol Rec, 2012, 87 (47): 461-476.
|
| 8 |
Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections[J]. Pediatr Clin North Am, 2013, 60 (2): 351-365.
|
| 9 |
Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study[J]. Lancet, 2018, 391 (10127): 1285-1300.
|
| 10 |
Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study[J]. Lancet Infect Dis, 2012, 12 (9): 687-695.
|
| 11 |
Monsalvo AC, Batalle JP, Lopez MF, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes[J]. Nat Med, 2011, 17 (2): 195-199.
|
| 12 |
Short KR, Kroeze EJBV, Fouchier RAM, et al. Pathogenesis of influenza-induced acute respiratory distress syndrome[J]. Lancet Infect Dis, 2014, 14 (1): 57-69.
|
| 13 |
Fukuyama S, Kawaoka Y. The pathogenesis of influenza virus infections: the contributions of virus and host factors[J]. Curr Opin Immunol, 2011, 23 (4): 481-486.
|
| 14 |
修燕，徐飚，姜庆五.严重急性呼吸综合征的流行和防治[J].中华传染病杂志,2003,21(3):196-198.
|
| 15 |
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia[J/OL]. N Engl J Med, 2020 [2020-02-21]. published online ahead of print Jan 29, 2020].
URL
|
| 16 |
国家卫生健康委办公厅.国家卫生健康委办公厅关于印发新型冠状病毒肺炎防控方案（第五版）的通知[EB/OL]. (2020-02-21) [2020-02-21].
URL
|
| 17 |
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395 (10223): 507-513.
|
| 18 |
Kurt-Jones EA, Orzalli MH, Knipe DM. Innate immune mechanisms and herpes simplex virus infection and disease[J]. Adv Anat Embryol Cell Biol, 2017 (223): 49-75.
|
| 19 |
Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity[J]. Cell, 2006, 124 (4): 783-801.
|
| 20 |
Murphy AA, Rosato PC, Parker ZM, et al. Synergistic control of herpes simplex virus pathogenesis by IRF-3, and IRF-7 revealed through non-invasive bioluminescence imaging[J]. Virology, 2013, 444 (1-2): 71-79.
|
| 21 |
Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concer[J]. Lancet, 2020, 395 (10223): 470-473.
|
| 22 |
Pichlmair A, Schulz O, Tan CP, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates[J]. Science, 2006, 314 (5801): 997-1001.
|
| 23 |
Weiland JE, Davis WB, Holter JF, et al. Lung neutrophils in the adult respiratory distress syndrome. Clinical and pathophysiologic significance[J]. Am Rev Respir Dis, 1986, 133 (2): 218-225.
|
| 24 |
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J/OL]. Lancet Respir Med, 2020 [2020-02-21]. published online ahead of print Feb 17, 2020].
URL
|
| 25 |
Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study[J]. Lancet Respir Med, 2016, 4 (4): 259-271.
|
| 26 |
Daviaud F, Grimaldi D, Dechartres A, et al. Timing and causes of death in septic shock[J]. Ann Intensive Care, 2015, 5 (1): 16.
|
| 27 |
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy[J]. Nat Rev Immunol, 2013, 13 (12): 862-874.
|
| 28 |
Wherry EJ, Day CL, Draenert R, et al. HIV-specific CD8 T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memory[J]. Virology, 2006, 353 (2): 366-373.
|
| 29 |
Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection[J]. J Virol, 2004, 78 (11): 5535-5545.
|
| 30 |
Fuller MJ, Khanolkar A, Tebo AE, et al. Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections[J]. J Immunol, 2004, 172 (7): 4204-4214.
|
| 31 |
El-Far M, Halwani R, Said E, et al. T-cell exhaustion in HIV infection[J]. Curr HIV/AIDS Rep, 2008, 5 (1): 13-19.
|
| 32 |
Griffin DE. Measles virus-induced suppression of immune responses[J]. Immunol Rev, 2010 (236): 176-189.
|
| 33 |
Grinde B. Herpesviruses: latency and reactivation-viral strategies and host response[J]. J Oral Microbiol, 2013 (5): 22766.
|
| 34 |
Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit[J]. Crit Care Med, 2009, 37 (8): 2350-2358.
|
| 35 |
Ong DSY, Bonten MJM, Spitoni C, et al. Epidemiology of multiple herpes viremia in previously immunocompetent patients with septic shock[J]. Clin Infect Dis, 2017, 64 (9): 1204-1210.
|
| 36 |
Walton AH, Muenzer JT, Rasche D, et al. Reactivation of multiple viruses in patients with sepsis[J]. PLoS One, 2014, 9 (6): e98819.
|
| 37 |
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock[J]. Crit Care Med, 2006, 34 (6): 1589-1596.
|
| 38 |
Abzug MJ, Michaels MG, Wald E, et al. A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis[J]. J Pediatric Infect Dis Soc, 2016, 5 (1): 53-62.
|
| 39 |
Nilsen AE, Aasen T, Halsos AM, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes[J]. Lancet, 1982, 2 (8298): 571-573.
|
| 40 |
De Clercq E, Li G. Approved antiviral drugs over the past 50 years[J]. Clin Microbiol Rev, 2016, 29 (3): 695-747.
|
| 41 |
Hotchkiss RS, Moldawer LL, Opal SM, et al. Sepsis and septic shock[J]. Nat Rev Dis Primers, 2016 (2): 16045.
|
| 42 |
Su JB. Vascular endothelial dysfunction and pharmacological treatment[J]. World J Cardiol, 2015, 7 (11): 719-741.
|
| 43 |
Leentjens J, Kox M, van der Hoeven JG, et al. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change[J]. Am J Respir Crit Care Med, 2013, 187 (12): 1287-1293.
|
| 44 |
Unsinger J, Burnham CA, McDonough J, et al. Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis[J]. J Infect Dis, 2012, 206 (4): 606-616.
|
| 45 |
Tomino A, Tsuda M, Aoki R, et al. Increased PD-1 expression and altered T cell repertoire diversity predict mortality in patients with septic shock: a preliminary study[J]. PLoS One, 2017, 12 (1): e0169653.
|
| 46 |
Rao M, Valentini D, Dodoo E, et al. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm[J]. Int J Infect Dis, 2017 (56): 221-228.
|
| 47 |
李晗宇，陈路芳，李金优，等.益生菌制剂对脓毒症小鼠生存情况的影响及机制研究[J/CD].中华危重症医学杂志(电子版),2017,10(5):289-295.
|
| 48 |
Zeng L, Kang R, Zhu S, et al. ALK is a therapeutic target for lethal sepsis[J]. Sci Transl Med, 2017, 9 (412): 5689.
|